Related Experiment Video
Updated: Aug 13, 2026
06:38
The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
Published on: December 19, 2025
1,026 experimental treatments in acute stroke
Victoria E O'Collins1, Malcolm R Macleod, Geoffrey A Donnan
1Neuroscience Lab, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia.
Annals of Neurology
|February 3, 2006
Summary
Neuroprotectant drugs in preclinical studies show no difference in efficacy between those that reached clinical trials and those that did not. This suggests potential issues in selecting the most effective drugs for stroke clinical trials.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Preclinical neuroprotectant studies raised hopes for clinical success, but outcomes have not matched expectations.
- This discrepancy prompts investigation into whether animal models are poor predictors or if optimal drugs are overlooked for clinical trials.
Purpose of the Study:
- To compare the experimental efficacy and testing scope of neuroprotectants that advanced to clinical use versus those only tested experimentally.
- To identify factors contributing to the limited success of neuroprotectant drug development in stroke.
Main Methods:
- Systematic literature search to identify neuroprotectants and their experimental efficacy reports.
- Analysis of controlled in vivo and in vitro studies using functional or histological endpoints.
- Statistical assessment of relationships between drug efficacy, mechanism, testing scope (STAIR criteria), and clinical trial status.
Main Results:
- No significant difference in experimental efficacy was found between clinically used neuroprotectants (114) and those tested only in animal models (912).
- Average improvement in focal models was comparable: 31.3% for clinical drugs vs. 24.4% for non-clinical drugs (p > 0.05).
- Scope of testing varied widely, and no correlation was observed between drug mechanism and efficacy.
Conclusions:
- The findings raise doubts about the selection process for drugs entering stroke clinical trials.
- This selection issue may contribute to the slow progress in developing effective stroke treatments.
- Enhanced rigor in animal study conduct, reporting, and analysis is crucial for translating research findings to clinical practice.
